These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 25341043

  • 1. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.
    Cell Death Dis; 2014 Oct 23; 5(10):e1489. PubMed ID: 25341043
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.
    Raulf N, El-Attar R, Kulms D, Lecis D, Delia D, Walczak H, Papenfuss K, Odell E, Tavassoli M.
    Br J Cancer; 2014 Nov 11; 111(10):1955-64. PubMed ID: 25314064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS.
    Exp Cell Res; 2012 Aug 01; 318(13):1564-76. PubMed ID: 22513214
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 Jun 15; 17(12):4019-30. PubMed ID: 21525171
    [Abstract] [Full Text] [Related]

  • 8. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.
    Mol Cancer Ther; 2007 Jul 15; 6(7):2103-12. PubMed ID: 17620439
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O, Sebbagh M, Mérino D, Micheau O, Bertoglio J, Bréard J.
    Oncogene; 2008 Oct 09; 27(46):6012-22. PubMed ID: 18560353
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B.
    Cancer Biol Ther; 2005 Jul 09; 4(7):781-6. PubMed ID: 16082182
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K, Székely-Szüts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhász H, Dominici M, Spano C, Luca Cervo G, Conte P, Houghton JA, Mihalik R, Kopper L, Peták I.
    Pathol Oncol Res; 2006 Jul 09; 12(3):133-42. PubMed ID: 16998592
    [Abstract] [Full Text] [Related]

  • 16. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV- and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy.
    Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C.
    Clin Cancer Res; 2019 Nov 01; 25(21):6463-6474. PubMed ID: 31266830
    [Abstract] [Full Text] [Related]

  • 17. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
    Fulda S.
    Oncotarget; 2011 May 01; 2(5):418-21. PubMed ID: 21789791
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.
    J Natl Cancer Inst; 2008 May 07; 100(9):649-62. PubMed ID: 18445820
    [Abstract] [Full Text] [Related]

  • 20. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M, Bittner S, Seibold K, Wajant H.
    Cell Death Dis; 2014 Dec 11; 5(12):e1570. PubMed ID: 25501831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.